Company news

Eledon Pharmaceuticals, Inc. news in 2025

Eledon Pharmaceuticals, Inc.'s news releases, calls and decks from 2025, newest first.

View company

Eledon Pharmaceuticals to Participate in the 37th Annual Piper Sandler Healthcare Conference

December 1, 2025

Eledon Reports Preliminary Data from First Six Patients with Type 1 Diabetes Treated with Tegoprubart as the Core Immunosuppressant Following Islet Transplantation in Investigator-Initiated Trial at UChicago Medicine

November 18, 2025

Eledon Pharmaceuticals Announces Recent Business Highlights and Third Quarter 2025 Financial Results

November 14, 2025

Eledon Pharmaceuticals Announces Pricing of $50 Million Underwritten Public Offering of Common Stock and Pre-Funded Warrants

November 12, 2025

Eledon Pharmaceuticals Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants

November 11, 2025

Eledon Presents Phase 2 BESTOW Trial Results for Tegoprubart for the Prevention of Rejection in Kidney Transplantation at the American Society of Nephrology’s Kidney Week 2025 Annual Meeting

November 6, 2025

Eledon Pharmaceuticals to Present at Guggenheim Second Annual Healthcare Innovation Conference

November 5, 2025

Eledon Pharmaceuticals to Present Results from Phase 2 BESTOW Trial of Tegoprubart for the Prevention of Rejection in Kidney Transplantation at the American Society of Nephrology Kidney Week 2025 Annual Meeting

October 17, 2025

Eledon Pharmaceuticals to Present at the 18th Congress of the International Xenotransplantation Association

September 24, 2025

Eledon Pharmaceuticals to Participate in Cantor Global Healthcare Conference 2025

August 29, 2025

Eledon Pharmaceuticals Reports Second Quarter 2025 Operating and Financial Results

August 14, 2025

Eledon Presents Updated Data from Ongoing Phase 1b Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation

August 6, 2025

Eledon Pharmaceuticals to Host a Conference Call to Discuss Updated Data from the Ongoing Phase 1b Trial of Tegoprubart in Kidney Transplantation Being Presented at the World Transplant Congress 2025

July 30, 2025

Updated Data from Eledon Pharmaceuticals’ Ongoing Phase 1b Trial of Tegoprubart in Patients Undergoing Kidney Transplantation to be Presented at the World Transplant Congress 2025

July 17, 2025

Eledon Pharmaceuticals to Host R&D Day on July 9, 2025 in New York City

June 25, 2025

Eledon Pharmaceuticals Reports First Quarter 2025 Operating and Financial Results

May 14, 2025

Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Operating and Financial Results

March 20, 2025

Eledon Pharmaceuticals to Participate in Leerink Partners Global Healthcare Conference

March 4, 2025

Eledon Pharmaceuticals Announces Use of Tegoprubart as Key Component of Immunosuppression Regimen in its Second Transplant of a Genetically Modified Pig Kidney into a Human

February 6, 2025

Decks in 2025